A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets

Myelofibrosis Clinical Trial

Official title:

A Phase I Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06024915
• Other study ID #: TQ05105-I-04
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: September 2023
• Est. completion date: December 2023

Study information

• Verified date: May 2023
• Source: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Contact: Xin Wang, MD, PhD
• Phone: 86-0531-68778331
• Email: xinw007[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-center, open, single-dose, self-controlled phase I clinical trial to evaluate the effects of metabolic enzyme inhibitors/inducers on in vivo metabolic and elimination of TQ05105 tablets, and the safety of metabolic enzyme inhibitors/inducers combined with TQ05105 tablets.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 40
• Est. completion date: December 2023
• Est. primary completion date: October 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• At the time of signing the informed consent, males or females between 18 and 45 years of age;

• Female weight = 45 kg, male weight = 50 kg, with a body mass index (BMI) between 19 and 26 kg/m2.

• Subjects in good health, as determined by a medical history, vital signs, physical examination, 12-lead electrocardiogram (ECG) and clinical laboratory evaluations;

• Subjects can comply with the study procedures, voluntarily participate in the study, and sign the informed consent in person.

Exclusion Criteria:

• Subjects: preexisting or existing circulatory system, endocrine system, nervous system, digestive system, respiratory system, genitourinary system, hematology, immunology, psychiatry and metabolic disorders or abnormalities, or related chronic or acute diseases, the investigator assesses that it is not appropriate to participate in the trial;

• Subjects with Systemic/local acute infection before taking the study drug;

• Subjects who have a history of specific allergies, or allergic conditions (such as allergies to two or more drugs, environments, or foods), or are known to be allergic to components or analogs of the study drug;

• Subjects who have difficulty in swallowing or have any gastrointestinal disorder that affects drug absorption at the time of screening;

• Subjects who cannot receive venous indwelling needle for blood sample collection;

• Subjects who drank regularly in the 6 months prior to first dosing, such as those who drank more than 14 units of alcohol per week or who had a positive alcohol breath test at the time of screening;

• Subjects who had a history of major surgery, or had taken the study drug, or had participated in other drug clinical trials within 3 months prior to initial dosing;

• Subjects who donated blood or lost significant amounts of blood within 3 months prior to initial dosing;

• Subjects who had used drugs within 3 months prior to first dosing, or tested positive for drugs, or had a history of drug abuse within 5 years prior to screening;

• Subjects who smoked more than 5 cigarettes per day in the 3 months prior to initial dosing or who could not stop using any tobacco products during the trial;

• Subjects who consumed excessive amounts of tea, coffee, and/or caffeinated beverages daily in the 30 days prior to initial dosing;

• Subjects who have used any drug that inhibits or induces liver metabolism of the drug in the 30 days prior to initial dosing;

• Subjects who have taken any prescription, over-the-counter, herbal, or health product in the 14 days prior to initial dosing;

• Subjects who have taken a special diet or other factors affecting drug absorption, distribution, metabolism, or excretion within 7 days prior to initial dosing;

• Subjects who ingested chocolate, any caffeinated, or xanthine-rich food or drink 48 hours before first dosing;

• Subjects who have special dietary requirements and cannot follow a uniform diet;

• Female subjects of child-bearing potential;

• Subjects judged by the investigator to be unsuitable to participate.

Related Conditions & MeSH terms

• Myelofibrosis
• Primary Myelofibrosis

Intervention

Drug:
• TQ05105 tablets
TQ05105 is a Janus kinase 2 (JAK2) inhibitor.
• Itraconazole capsule
Itraconazole is a strong inhibitor of cytochrome P450 3A (CYP3A).
• Rifampicin Capsule
Rifampicin is a strong inducer of CYP3A.

Locations

Country	Name	City	State
China	Shandong Provincial Hospital	Jinan	Shandong

Sponsors (1)

Lead Sponsor	Collaborator
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum plasma concentration (Cmax)	Maximum plasma drug concentration after administration.	Up to 10 days.
Primary	Time to reach Cmax (Tmax)	Time to reach the maximum plasma concentration after administration.	Up to 10 days.
Primary	Elimination half-life (t1/2)	The elimination half-life (t1/2) after oral dose of TQ05105 tablets and Itraconazole capsule.	Up to 6 days.
Secondary	Occurrence of adverse events (AE)	Including all adverse events (AE) and serious adverse events (SAE).	Up to 30 days.